Form 8-K - Current report:
SEC Accession No. 0001193125-25-005659
Filing Date
2025-01-14
Accepted
2025-01-14 07:08:41
Documents
15
Period of Report
2025-01-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d868307d8k.htm   iXBRL 8-K 31155
2 EX-99.1 d868307dex991.htm EX-99.1 16843
6 GRAPHIC g868307g0114004241000.jpg GRAPHIC 2997
  Complete submission text file 0001193125-25-005659.txt   178990

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgnx-20250114.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgnx-20250114_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgnx-20250114_pre.xml EX-101.PRE 10808
17 EXTRACTED XBRL INSTANCE DOCUMENT d868307d8k_htm.xml XML 3500
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Filer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37553 | Film No.: 25527747
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)